NCT06679374View on ClinicalTrials.gov

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Parkinson Disease
Interventions
DRUG

Placebo

Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.

DRUG

Varenicline

Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.

Trial Locations (1)

48109

RECRUITING

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Vikas Kotagal

OTHER